Chemistry:Relacorilant
Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.[1] Relacorilant is a glucocorticoid receptor antagonist.[1]
The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]
Relacorilant was approved for medical use in the United States in March 2026.[2][3]
Medical uses
Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.[1]
Adverse effects
The US prescribing information includes a contraindication for people who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.[2] The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]
History
Efficacy was evaluated in ROSELLA (NCT05257408), a multicenter, open-label, trial in 381 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.[2] Participants were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required.[2] The trial excluded participants who required chronic or frequent use of glucocorticoids.[2] Participants were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.[2]
References
- ↑ 1.0 1.1 1.2 Cite error: Invalid
<ref>tag; no text was provided for refs namedLifyorli FDA label - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "FDA approves relacorilant with nab-paclitaxel for platinum-resistant". 25 March 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or.
This article incorporates text from this source, which is in the public domain.
- ↑ Kansteiner, Fraiser (2026-03-25). "Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer". https://www.fiercepharma.com/pharma/corcepts-lead-drug-bounces-back-fda-snub-1st-approval-lifyorli-ovarian-cancer.
External links
- Clinical trial number NCT05257408 for "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer" at ClinicalTrials.gov
 |  |
